Preclinical studies on the anti-migraine drug, sumatriptan.

From serotonin receptor classification to the antimigraine drug sumatriptan.

The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater.

Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks.

Comparative effects of the antimigraine drugs sumatriptan and ergotamine on the distribution of cardiac output in anaesthetized pigs.

1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.

Drug therapy in stroke: from preclinical to clinical studies.

Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig.

Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.

The impact of preclinical irreproducibility on drug development.

Pharmacology of antimigraine drugs.

The failure to detect drug-induced sensory loss in standard preclinical studies.

Sumatriptan.

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies.

Statistical considerations for preclinical studies.

Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache.

Mitigating risk in academic preclinical drug discovery.

5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy.

Preclinical and clinical studies targeting stroke.

Stem cells in preclinical spine studies.

Oncolysis by paramyxoviruses: preclinical and clinical studies.

Preclinical research: Design animal studies better.

Review of preclinical studies with ofloxacin.

Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group.

Suggest Documents

From serotonin receptor classification to the antimigraine drug sumatriptan.

The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater.

Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks.

Comparative effects of the antimigraine drugs sumatriptan and ergotamine on the distribution of cardiac output in anaesthetized pigs.

1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.

Drug therapy in stroke: from preclinical to clinical studies.

Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig.

Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.

The impact of preclinical irreproducibility on drug development.

Pharmacology of antimigraine drugs.

The failure to detect drug-induced sensory loss in standard preclinical studies.

Sumatriptan.

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies.

Statistical considerations for preclinical studies.

Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache.

Mitigating risk in academic preclinical drug discovery.

5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy.

Preclinical and clinical studies targeting stroke.

Stem cells in preclinical spine studies.

Oncolysis by paramyxoviruses: preclinical and clinical studies.

Preclinical research: Design animal studies better.

Review of preclinical studies with ofloxacin.

Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group.

Preclinical studies on the anti-migraine drug, sumatriptan.

Recommend Documents

Follow Us